In an open letter to Congress, pharmaceutical companies said that allowing Medicare to negotiate drug prices “would threaten patients’ access to medicines and sacrifice future medical advances,” lobbying group PhRMA announced.
The PD-1 inhibitor camrelizumab joined other drugs in the class in producing a beneficial effect in advanced/metastatic esophageal cancer. (JAMA)
BeiGene announced that the FDA granted accelerated approval to the Bruton tyrosine kinase inhibitor zanubrutinib (Brukinsa) for previously treated relapsed/refractory marginal zone lymphoma.
A British woman with incurable ovarian cancer is part of a team that will begin to row across the Atlantic Ocean in December to raise money for organizations that support cancer research. (BBC)
A group of stem-cell transplant recipients had good immune response to two doses of the Pfizer/BioNTech COVID vaccine. (JAMA Network Open)
Three Scottish women have died of cervical cancer after being wrongly excluded from the country’s screening program. (BBC)
Almost 70% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma responded to the bispecific antibody epcoritamab. (The Lancet)
More evidence that low-dose radiation can transform “cold” tumors into “hot” ones that are more responsive to immunotherapy. (Ludwig Cancer Research)
State legislation affecting health insurance coverage had a favorable impact on earlier diagnosis of breast cancer. (Penn State)
“Saturday Night Live” alum Norm Macdonald, 61, died 9 years after diagnosis of an undisclosed type of cancer. (Deadline)
The American Association for Cancer Research announced the formation of a working group to support research into cancer prevention.
Favorable 5-year survival data have begun to roll in for patients with kidney cancer. (FiercePharma)